New ambr 15 fermentation micro-scale bioreactor system provides enhanced microbial strain screening
New ambr 15 fermentation micro bioreactor system designed to enhance microbial strain screening applications.
The system offers parallel processing and walk-away control of 24 micro bioreactors.
Sartorius Stedim Biotech (SSB) has introduced the new ambr 15 fermentation system, an automated micro bioreactor system designed to enhance microbial strain screening with advanced capabilities supporting fed-batch microbial cultures.
The new system, based on the gold-standard ambr 15 micro bioreactor technology, has been designed to meet the requirements of microbial fermentation. It comprises 24 single-use stirred micro bioreactors (each with an 8–12 mL working volume) integrated to a user-friendly, automated workstation. The system offers parallel processing and walk-away control of 24 micro bioreactors, providing fermentation scientists with efficient, consistent results from an enhanced early stage screening platform.
ambr 15 fermentation has been designed to deliver high oxygen transfer rates, rapid pH and feed additions and is ideally suited for assessing the effects of different strains with microbial cultures. The ambr 15 fermentation measures pH and DO every 12 seconds and there are pumped liquid lines for base and feed addition in each micro bioreactor, enabling tight pH control and a semicontinuous feed supply. Additionally, the 10-mL working volume allows multiple samplings throughout the fermentation run to assess culture growth and protein production, thus providing more detailed process understanding.
The single-use micro bioreactor vessel contains an impeller suitable for fermentation and provides enhanced capability compared to shaking culture systems. The pH range of 6–8 is ideal for biopharm E. coli applications and cultures with similar requirements. As the ambr 15 vessels are single use and supplied sterile this eliminates cleaning and sterilization time, thus decreasing turnaround times between runs by many hours.
Dr Barney Zoro, ambr Product Manager at SSB explained: “Scientists have been trying to model microbial fermentation and screen microbial strains using shake plates and flasks but these devices are poor early-stage models as they are not able to achieve representative cell densities, and do not allow monitoring and control of pH or DO. With these issues in mind, we developed ambr 15 fermentation and have data showing system consistency, repeatability and predictive selection of strains. This demonstrates that the system is an excellent tool for enhanced screening applications and we are confident that fermentation scientists will significantly reduce their time and resource demands when performing enhanced microbial strain selection studies using an ambr 15 fermentation system.”
Related News
-
News Federal judge blocks Colorado's unprecedented price cap on Amgen's Enbrel
A US federal court has halted Colorado's attempt to impose a US$31,200 annual price cap on Amgen's arthritis drug Enbrel, ruling that the pharmaceutical company would likely suffer irreparable harm. The decision represents a significant blow to... -
News Protecting life-saving therapies: CPHI Online Podcast Series
The latest episode of the CPHI Podcast Series dives into a critical challenge facing the pharmaceutical industry: ensuring the integrity of temperature-sensitive medications and biologics through advanced predictive technology.
-
News 2026 Outsourcing Outlook Update - pharma at a crossroads
The pharmaceutical contract development and manufacturing organisation (CDMO) sector is experiencing unprecedented transformation, driven by evolving therapeutic complexities, geopolitical tensions, and the growing demand for specialised manufacturing ... -
News Roche maintains German investment commitment whilst rivals scale back
Pharmaceutical giant Roche has reaffirmed its commitment to investing in Germany, standing firm even as competitors Eli Lilly and Boehringer Ingelheim dramatically reduce their planned investments in response to controversial healthcare reforms.
-
News Women in Pharma: The History of CPHI Women in Japan
Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive. -
News EU drafts deal to end essential medicines shortage
European negotiators have agreed new legislation to tackle persistent shortages of essential medicines by prioritising supply security over price in public procurement and supporting domestic pharmaceutical manufacturing with strategic funding.
-
News Thermo Fisher Scientific offloads microbiology business to PE firm Astorg
The life sciences giant is divesting its global microbiology unit, which generated $645 million in revenue last year, to the pan-European private equity firm as part of an active portfolio management strategy. The transaction is expected to close in th... -
News The Shift: Why Sustainability is Moving to the Centre of CPHI Milan 2026
CPHI Online contributor David Roach takes a look at how conversations around sustainability in the pharmaceutical industry can and must be transformed into actionable deliveries, and what the inaugural CPHI Sustainability Summit means for the industry.